Even at high cost, blood cancer drugs provide a good value, an analysis by Tufts Medical Center researchers found.
Late next month, NCI is expected to publish the new criteria it uses to bestow designations on America’s network of cancer centers.
Tufts Researchers Say Blood Cancer Drugs Are a Good Value; Kantarjian Disagrees
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Members of the National Cancer Advisory Board’s ad hoc Working Group on Extramural Research Concepts and Programs at a recent meeting struggled to define the new group’s the role and raised concerns about some initial growing pains.
Earlier this week, FDA granted an accelerated approval to dostarlimab-gxly (Jemperli), for adults with previously untreated stage 2 or stage 3 rectal cancer that is mismatch repair deficient or microsatellite instability-high, marking a celebratory moment for the field.
Keaton Herzer had never even heard of cholangiocarcinoma when he was diagnosed in 2025.Â
Neeha Zaidi, MD, is turning the tables on pancreatic cancer. Mutations to a gene called KRAS—a cancer driver common to almost all pancreatic cancers—are now a target for prevention and treatment.
HHS, through the recently announced Office of Women’s Health, announced taht it will be pursuing a collaboration with the Agency for Healthcare Research and Quality and DenseBreast-info.org to strengthen breast cancer screening, expand breast density education, and improve timely diagnostic follow-up, particularly for midlife women.
